A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer
Authors
Keywords
-
Journal
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-15
DOI
10.1007/s10637-021-01146-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antibody–Drug Conjugates for Cancer Therapy
- (2020) Umbreen Hafeez et al. MOLECULES
- Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis
- (2019) Muneer J. Al-Husseini et al. BMC CANCER
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- Antibody-Drug Conjugates: A Comprehensive Review
- (2019) Puregmaa Khongorzul et al. MOLECULAR CANCER RESEARCH
- FGFR3-TACC3 fusion in solid tumors: mini review
- (2016) Ricardo Costa et al. Oncotarget
- Targeting FGFR Signaling in Cancer
- (2015) M. Touat et al. CLINICAL CANCER RESEARCH
- Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
- (2015) Joshua Seth Eaton et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- FGFR3 Expression in Primary Invasive Bladder Cancers and Matched Lymph Node Metastases
- (2015) Rafal Turo et al. JOURNAL OF UROLOGY
- FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder
- (2014) Elizabeth A. Guancial et al. Cancer Medicine
- FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy11This work was supported by Grant CB-2011-04-01 from Korean Foundation for Cancer Research grant and by a Global Frontier Project Grant (NRF-M1AXA002-2010-0029795) of the National Research Foundation funded by the Ministry of Education, Science and Technology of Korea.
- (2013) Ji-Youn Sung et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Mechanisms of FGFR-mediated carcinogenesis
- (2012) Imran Ahmad et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma
- (2011) Hikmat A Al-Ahmadie et al. JOURNAL OF PATHOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Critical aspects of the Bayesian approach to phase I cancer trials
- (2008) Beat Neuenschwander et al. STATISTICS IN MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now